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Photoreceptors are the neurons of the central nervous system that help mediate the bulk of our light responses. They form large part of our light-sensitive tissue called the retina, in the back of the eye. There are two major types of photoreceptors: rods and cones. Rods respond to dim light stimuli (starlight from a dark sky) but get bleached at higher light intensities. Cones, on the other hand, are less light sensitive and have the ability to respond to a wider range of light stimuli. They are, therefore, responsible for much of our vision during the day as well as with artificial bright lights during the nighttime. Given that photoreceptors are the major components of our vision, retinal degeneration due to photoreceptor dysfunction is the largest cause of inherited blindness in the world [1] .
RARE DISEASES -CLINICAL & COMMERCIAL DEVELOPMENTS
"Developing a mutation-independent approach that will deliver even low levels of the functional CEP290 could be sufficient to mitigate not only retinal degeneration, but also other ciliopathy-associated phenotypes in syndromic diseases."
Photoreceptor degeneration is highly genetically heterogeneous with nearly 200 cloned genes [2] . These numbers seem to account for a majority of monogenic forms of retinal degenerative diseases. Among these, retinitis pigmentosa (RP) is the most common form of inherited retinal degeneration, with a prevalence of approximately 1 in 3000 people worldwide [3] . RP patients show a wide range of age of onset (15-40 years of age) and typically exhibit dysfunction of rod photoreceptors, due to which they start complaining of night blindness. This disorder then progresses to complete blindness due to the subsequent loss of cone photoreceptors. Hence, RP is also termed rod-cone degeneration. Other forms of inherited photoreceptor degenerative diseases show both rod and cone dysfunction at the same time or exhibit a predominant involvement of only cones or of cones followed by rods (cone-rod degeneration). RP is also commonly observed in syndromic diseases with extraocular manifestations, the majority of which are classified as ciliopathies. These include Joubert Syndrome (cerebellar defects), Bardet-Biedl Syndrome (polydactyly and obesity), Senior-Loken Syndrome (renal defects), and Usher Syndrome (hearing disorders) [4] [5] [6] .
A relatively earlier onset form of photoreceptor degeneration is Leber congenital amaurosis (LCA) [7] . It Moreover, CEP290 mutations also result in syndromic ciliopathies, which are likely due to low or non-functional protein. While the focus on the deep intronic mutation is encouraging and will provide new knowledge to develop the specific therapeutics, these approaches will only be suitable for one type of CEP290 mutations. Developing a mutation-independent approach that will deliver even low levels of the functional CEP290 could be sufficient to mitigate not only retinal degeneration but also other ciliopathy-associated phenotypes in syndromic diseases.
As mentioned above, the conventional approach to deliver the fulllength CEP290 gene using AAV vectors as vehicles would not be suitable. We and others have shown the involvement of the distinct domains of CEP290 in its interaction with other ciliary proteins and localization to cilia [22-25]. The deletion of some CEP290 domains does not significantly alter cilia formation but results in ciliary dysfunction (Cep290rd16 mouse model) [11, 14, 24]. These studies suggested that different domains of CEP290 are involved in distinct steps of cilia formation and modulating its function. Based on this knowledge, we constructed shorter forms of the CEP290 gene (miniCEP290) that are deliverable by AAV and can retain at least partial function as determined in cilia growth assays [26] . A similar approach has been used to mitigate muscular dystrophy due to dystrophin mutations [27] . We identified that miniCEP290s could delay the progression of photoreceptor dysfunction and degeneration when delivered subretinally in a Cep290-LCA mouse model. The treated retinas showed ~30% increase in photoreceptor function, improved photoreceptor morphology and delayed photoreceptor cell death. However, the improvement in the function and morphology progressively declined after 8 weeks of age.
Developing a suitable and longer-lasting strategy for CEP290-gene therapy remains a challenge in the field. One of the most important criteria to evaluate the efficacy of any gene therapy is the use of an appropriate testing platform. 
